cilomilast has been researched along with dinoprostone in 5 studies
Studies (cilomilast) | Trials (cilomilast) | Recent Studies (post-2010) (cilomilast) | Studies (dinoprostone) | Trials (dinoprostone) | Recent Studies (post-2010) (dinoprostone) |
---|---|---|---|---|---|
162 | 13 | 42 | 29,105 | 1,346 | 6,357 |
Protein | Taxonomy | cilomilast (IC50) | dinoprostone (IC50) |
---|---|---|---|
Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | 0.0155 | |
Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | 0.0031 | |
Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | 0.0021 | |
Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | 0.002 | |
Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | 0.0087 | |
Prostacyclin receptor | Homo sapiens (human) | 0.26 | |
Prostaglandin E2 receptor EP2 subtype | Rattus norvegicus (Norway rat) | 0.0052 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ammit, AJ; Amrani, Y; Hay, DW; Hoffman, RK; Lazaar, AL; Panettieri, RA; Penn, RB; Torphy, TJ | 1 |
Ezeamuzie, CI | 1 |
Abe, S; Barnette, MS; Cieslinski, L; Fang, Q; Kobayashi, T; Kohyama, T; Liu, X; Rennard, SI; Wen, FQ | 1 |
Bäumer, W; Kietzmann, M | 1 |
Fang, Q; Liu, X; Ma, Y; Michalski, J; Rennard, SI; Wang, J | 1 |
5 other study(ies) available for cilomilast and dinoprostone
Article | Year |
---|---|
Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphate.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Bucladesine; Cells, Cultured; Chemokine CCL5; Colforsin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Dinoprostone; Dose-Response Relationship, Drug; Humans; Interleukin-6; Muscle, Smooth; NF-kappa B; Nitriles; Phosphodiesterase Inhibitors; RNA, Messenger; Time Factors; Trachea; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2000 |
Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenylyl Cyclases; Adult; Albuterol; Benzamides; Cell Degranulation; Colforsin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Activation; Eosinophil Peroxidase; Eosinophils; Histamine; Humans; Nitriles; Peroxidases; Phosphodiesterase Inhibitors; Pyridines; Rolipram; Superoxides; Theophylline | 2001 |
Cytokines modulate cilomilast response in lung fibroblasts.
Topics: Bronchodilator Agents; Carboxylic Acids; Cell Movement; Cells, Cultured; Collagen; Cyclohexanecarboxylic Acids; Cytokines; Dinoprostone; Dose-Response Relationship, Drug; Fetus; Fibroblasts; Humans; Interleukin-1; Interleukin-4; Lung; Nitriles; Recombinant Proteins | 2004 |
Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Carboxylic Acids; Cell Proliferation; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Cyclosporine; Dermatitis, Atopic; Dinoprostone; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Keratinocytes; Mice; Nitriles; Phosphodiesterase Inhibitors; Species Specificity | 2007 |
PGE 2 desensitizes β -agonist effect on human lung fibroblast-mediated collagen gel contraction through upregulating PDE4.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclohexanecarboxylic Acids; Dinoprostone; Fibroblasts; Gels; Gene Expression Regulation; Humans; Indomethacin; Lung; Nitriles; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Up-Regulation | 2013 |